ATE183087T1 - Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen - Google Patents

Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen

Info

Publication number: ATE183087T1
Authority: AT; Austria
Prior art keywords: beta; hydroxy; hmb; humans; nitrogen retention
Prior art date: 1992-12-23

Application number

AT94903563T

Other languages

English (en)

Inventor

Steven L Nissen

Paul J Flakkol

Naji N Abumrad

Original Assignee

Univ Iowa State Res Found Inc

Univ Vanderbilt

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-12-23

Filing date

1993-12-09

Publication date

1999-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25542600&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE183087(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-12-09 Application filed by Univ Iowa State Res Found Inc, Univ Vanderbilt filed Critical Univ Iowa State Res Found Inc

1999-08-15 Application granted granted Critical

1999-08-15 Publication of ATE183087T1 publication Critical patent/ATE183087T1/de

Links

IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 title abstract 8
AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 title abstract 6
229910052757 nitrogen Inorganic materials 0.000 title abstract 4
230000014759 maintenance of location Effects 0.000 title abstract 2
239000002253 acid Substances 0.000 title 1
102000004169 proteins and genes Human genes 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
238000001802 infusion Methods 0.000 abstract 1
238000001990 intravenous administration Methods 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
230000002485 urinary effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Obesity (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Emergency Medicine (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT94903563T 1992-12-23 1993-12-09 Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen ATE183087T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/996,187 US5348979A (en)	1992-12-23	1992-12-23	Method of promoting nitrogen retention in humans

Publications (1)

Publication Number	Publication Date
ATE183087T1 true ATE183087T1 (de)	1999-08-15

Family

ID=25542600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94903563T ATE183087T1 (de)	1992-12-23	1993-12-09	Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen

Country Status (9)

Country	Link
US (1)	US5348979A (de)
EP (1)	EP0637239B1 (de)
JP (1)	JP2925326B2 (de)
AT (1)	ATE183087T1 (de)
AU (1)	AU664511B2 (de)
CA (1)	CA2129541C (de)
DE (1)	DE69325998T2 (de)
ES (1)	ES2134340T3 (de)
WO (1)	WO1994014429A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5597843A (en) *	1995-06-07	1997-01-28	Houghten Pharmaceuticals	Use of a substituted 1,3-benzodioxole to reduce a wasting condition
US5756469A (en) *	1996-07-26	1998-05-26	Beale; Paxton K.	Composition of pyruvate and anti-cortisol compounds and method for increasing protein concentration in a mammal
US5716926A (en) *	1996-07-26	1998-02-10	Paxton K. Beale	Composition of pyruvate and protein and method for increasing protein concentration in a mammal
US6316038B1 (en)	1997-03-17	2001-11-13	Btg International Limited	Therapeutic compositions
US6323237B1 (en) *	1997-03-17	2001-11-27	Btg International Limited	Therapeutic compositions
US20090253781A1 (en) *	2002-05-24	2009-10-08	Btg International Limited	Therapeutic compositions
US6103764A (en) *	1997-11-07	2000-08-15	Iowa State University Research Foundation, Inc.	Method for increasing the aerobic capacity of muscle
US6031000A (en) *	1998-06-23	2000-02-29	Iowa State University Research Foundation, Inc.	Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use
WO2000043017A1 (en) *	1999-01-21	2000-07-27	Steroidogenesis Inhibitors International	Composition of anti-hiv drugs and anti-cortisol compounds and method for decreasing the side effects of anti-hiv drugs in a human
CA2447417C (en) *	2001-05-18	2011-10-04	Lonza Ag	Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate
US20040048925A1 (en) *	2002-09-09	2004-03-11	Wiley David B.	Composition and method for enhancing the bioavailability of calcium and magnesium in dietary supplements and food additives
US20040106678A1 (en) *	2002-09-17	2004-06-03	Dobbins Thomas A	Compositions for the parenteral administration of calcium and magnesium
US6812249B2 (en) *	2003-03-04	2004-11-02	Sal Abraham	Process for preparing a 3-hydroxy-3-methylbutyrate amino acid salt and method of use
US20050215640A1 (en) *	2004-03-26	2005-09-29	Baxter Jeffrey H	HMB compositions and uses thereof
GB0420856D0 (en) *	2004-09-20	2004-10-20	Ketocytonyx Inc	Cns modulators
EP1778213B1 (de)	2004-07-16	2017-04-05	BTG International Limited	Verfahren zur herstellung oligomerer verbindungen
EP1778615A4 (de) *	2004-07-20	2010-01-06	Btg Int Ltd	Oligomere ketonverbindungen
EP1778212A4 (de) *	2004-07-23	2010-12-08	Btg Int Ltd	Ketogene saccharide
EP1793813A4 (de) *	2004-09-21	2011-05-18	Btg Int Ltd	Behandlung von adhd
DK1796658T3 (en) *	2004-09-21	2016-06-27	Btg Int Ltd	dopaminergic mimetics
EP1973426A2 (de) *	2005-11-03	2008-10-01	Southwest Immunology Inc.	Zusammensetzungen für die vorbeugung und linderung von muskelkater
NZ568611A (en)	2005-12-19	2011-11-25	Abbott Lab	Use of beta-hydroxy-beta-methylbutyrate to modulate the imbalance in type 1 and type 2 cytokine production
EP2381784B1 (de) *	2008-12-09	2018-07-11	Metabolic Technologies, Inc.	Ernährungsmässiger eingriff zur verbesserung der muskelfunktion und -stärke
US9539224B2 (en)	2008-12-09	2017-01-10	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9770424B2 (en)	2008-12-09	2017-09-26	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9259430B2 (en)	2008-12-09	2016-02-16	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US9707241B2 (en)	2008-12-09	2017-07-18	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
US11173167B2 (en)	2008-12-09	2021-11-16	Metabolic Technologies, Inc.	Nutritional intervention for improving muscular function and strength
CN102762097B (zh) *	2009-12-18	2015-06-17	代谢科技有限公司	改进的给药β-羟基-β-甲基丁酸(HMB)的方法
US9693577B2 (en)	2010-01-29	2017-07-04	Abbott Laboratories	Method of preparing a nutritional powder comprising spray dried HMB
WO2011094557A1 (en)	2010-01-29	2011-08-04	Abbott Laboratories	Nutritional emulsions comprising calcium hmb
EP2461704B1 (de)	2010-01-29	2013-10-09	Abbott Laboratories	Aseptisch verpackte nahrungsflüssigkeiten mit hmb
TWI526161B (zh) *	2010-06-10	2016-03-21	亞培公司	包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
AU2013312113B2 (en)	2012-09-10	2018-08-02	Metabolic Technologies, LLC	Composition of HMB and ATP and methods of use
US20150057346A1 (en) *	2013-08-23	2015-02-26	Abbott Laboratories	Methods of maintaining intramuscular myoglobin levels, maintaining maximal aerobic capacity, and enhancing the oxidative capacity of muscle in a subject
PT3349745T (pt)	2015-09-16	2024-03-18	Metabolic Tech Inc	Composições e métodos de utilização de beta-hidroxi-beta metilbutirato (hmb) para melhorar a recuperação de traumatismos de tecidos moles
US12208073B2 (en)	2015-09-16	2025-01-28	Metabolic Technologies, LLC	Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
CA3011981C (en)	2016-01-21	2024-01-16	Metabolic Technologies, Inc.	Compositions and methods of use of .beta.-hydroxy-.beta.-methylbutyrate (hmb) for modulating autophagy and lipophagy
PT3528801T (pt)	2016-10-21	2024-10-21	Metabolic Tech Llc	Composições e métodos de utilização de beta-hidroxi-beta-metilbutirato (hmb) e probióticos
JOP20190146A1 (ar)	2016-12-19	2019-06-18	Axcella Health Inc	تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
EP3668499A1 (de)	2017-08-14	2020-06-24	Axcella Health Inc.	Aminosäurezusammensetzungen zur behandlung von lebererkrankungen
WO2019246225A1 (en)	2018-06-20	2019-12-26	Axcella Health Inc.	Compositions and methods for the treatment of fat infiltration in muscle
JP7202800B2 (ja) *	2018-07-13	2023-01-12	ライオン株式会社	水分散性組成物、食品組成物、水分散液及び泡立ち抑制方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4100293A (en) *	1974-04-15	1978-07-11	The Johns Hopkins University	Treatment of hepatic disorders with therapeutic compositions comprising keto analogs of essential amino acids
JPS51104039A (de) *	1975-03-07	1976-09-14	Sankyo Kasei Kogyo Kk
US4677121A (en) *	1985-01-22	1987-06-30	The Johns Hopkins University	Method of inhibiting muscle protein degradation
US4760090A (en) *	1986-03-11	1988-07-26	Iowa State University Research Foundation, Inc.	Method of feeding ketoisocaproate to cattle and sheep
US4764531A (en) *	1986-03-11	1988-08-16	Iowa State University Research Foundation, Inc.	Method of feeding ketoisocaproate to laying chickens
SE8803144L (sv) *	1988-09-07	1990-03-08	Kabivitrum Ab	Energisubstrat
DE3943424A1 (de) *	1989-12-30	1991-07-04	Nephro Medica Pharma	Infusions- und injektionsloesung zur intravenoesen verabreichung
US5087472A (en) *	1990-01-30	1992-02-11	Iowa State University Research Foundation, Inc.	Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) *	1990-01-30	1991-07-02	Iowa State University Research Foundation, Inc.	Method of raising meat producing animals to increase lean tissue development
US4992470A (en) *	1990-02-08	1991-02-12	Iowa State University Research Foundation, Inc.	Method of enhancing immune response of mammals
US5097472A (en) *	1990-02-22	1992-03-17	Chenausky Peter P	Preionized transversely excited laser

1992
- 1992-12-23 US US07/996,187 patent/US5348979A/en not_active Expired - Lifetime
1993
- 1993-12-09 AT AT94903563T patent/ATE183087T1/de active
- 1993-12-09 AU AU57463/94A patent/AU664511B2/en not_active Expired
- 1993-12-09 CA CA002129541A patent/CA2129541C/en not_active Expired - Lifetime
- 1993-12-09 WO PCT/US1993/011993 patent/WO1994014429A1/en not_active Ceased
- 1993-12-09 DE DE69325998T patent/DE69325998T2/de not_active Expired - Lifetime
- 1993-12-09 ES ES94903563T patent/ES2134340T3/es not_active Expired - Lifetime
- 1993-12-09 EP EP94903563A patent/EP0637239B1/de not_active Expired - Lifetime
- 1993-12-09 JP JP6515213A patent/JP2925326B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
WO1994014429A1 (en)	1994-07-07
ES2134340T3 (es)	1999-10-01
AU664511B2 (en)	1995-11-16
JPH07507569A (ja)	1995-08-24
EP0637239A4 (de)	1996-12-04
DE69325998D1 (de)	1999-09-16
US5348979A (en)	1994-09-20
CA2129541A1 (en)	1994-07-07
JP2925326B2 (ja)	1999-07-28
DE69325998T2 (de)	2000-01-05
CA2129541C (en)	1999-05-11
AU5746394A (en)	1994-07-19
EP0637239A1 (de)	1995-02-08
EP0637239B1 (de)	1999-08-11

Publication	Publication Date	Title
ATE183087T1 (de)	1999-08-15	Verwendung von beta-hydroxy-beta- methylbutyratsäuere zur förderung der stickstoffzurückhaltung beim menschen
CA2142314A1 (en)	1994-03-31	Method of Reducing Blood Levels of Total Cholesterol and Low-Density Lipoprotein Cholesterol
ATE158182T1 (de)	1997-10-15	Arzneimittel sowie deren herstellung und deren verwendung bei der bekämpfung von schmerzen und/oder entzündungen an tieren und menschen
BR9811825A (pt)	2000-08-15	Uso de lactobacillus para redução do nìvel de fibrinogênio no sangue
DE69333321D1 (de)	2004-01-08	Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DK0850068T3 (da)	2005-08-15	Lipidekstrakt med antiinflammatorisk aktivitet
ATE81984T1 (de)	1992-11-15	Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
ATE288772T1 (de)	2005-02-15	Sicherheitsmechanismus zum vorbeugen von unbeabsichtigter patienteninjektion sowie methode
KR950031063A (ko)	1995-12-18	프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
DE60115432D1 (de)	2006-01-05	Apoptotische körper zur verwendung in der behandlung von t-zell-vermittelten- und entzündungserkrankungen
ATE94763T1 (de)	1993-10-15	Medikament zur behandlung von fibrotischer stoerung und antifibrotische verbindung.
Verbov	1980	Cutaneous polyarteritis nodosa in a young child.
Miller	1953	Acute disseminated encephalomyelitis treated with ACTH
DE3575671D1 (de)	1990-03-08	Verwendung von saccharomyces-hefen fuer die herstellung eines arzneimittels gegen amoebiasis.
TWI263502B (en)	2006-10-11	Pharmaceutical preparation for treating ischemic disease of heart or limbs
Noble	1989	Failure of cefotaxime in the treatment of Yersinia enterocolitica sepsis despite in vitro susceptibility.
RU97115801A (ru)	1999-06-27	Способ лечения стенозирующих ларинготрахеитов у детей
EP0880967A3 (de)	1999-02-10	Nephroprotektive Arzneimittel
Zachariah	1984	Effective penetration of doxycycline into the serum and aqueous humor
RU95109228A (ru)	1997-06-10	Способ лечения трофических язв
Cherng et al.	2000	Acute aphesia following tourniquet release in intravenous regional anesthesia with 0.75% lidocaine
ATE83931T1 (de)	1993-01-15	Methode fuer die behandlung von viraler gehirnentzuendung.
ATE40795T1 (de)	1989-03-15	Verwendung eines zerebral und peripher wirkenden antihypoxidotikums.
Patterson et al.	1984	Psychosexual study of patients and non-patient homosexual groups.
ES8500055A1 (es)	1984-10-01	Procedimiento para la obtencion de un medicamento a base de un derivado de pirazolinona.